ES2955171T3 - Aplicaciones CE-Western para el desarrollo de anticuerpos - Google Patents
Aplicaciones CE-Western para el desarrollo de anticuerpos Download PDFInfo
- Publication number
- ES2955171T3 ES2955171T3 ES19218272T ES19218272T ES2955171T3 ES 2955171 T3 ES2955171 T3 ES 2955171T3 ES 19218272 T ES19218272 T ES 19218272T ES 19218272 T ES19218272 T ES 19218272T ES 2955171 T3 ES2955171 T3 ES 2955171T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- interest
- sample
- antibodies
- capillaries
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011161 development Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 181
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 109
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 109
- 235000018102 proteins Nutrition 0.000 claims abstract description 107
- 235000004252 protein component Nutrition 0.000 claims abstract description 47
- 238000005251 capillar electrophoresis Methods 0.000 claims abstract description 19
- 230000003100 immobilizing effect Effects 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims description 52
- 238000001514 detection method Methods 0.000 claims description 44
- 239000000356 contaminant Substances 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003550 marker Substances 0.000 claims description 19
- 239000007850 fluorescent dye Substances 0.000 claims description 17
- 101001074414 Homo sapiens Putative phospholipase B-like 2 Proteins 0.000 claims description 15
- 102100036164 Putative phospholipase B-like 2 Human genes 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 12
- 238000011068 loading method Methods 0.000 claims description 11
- 239000000959 ampholyte mixture Substances 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 description 26
- 239000000499 gel Substances 0.000 description 16
- 241000894007 species Species 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 239000000758 substrate Substances 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000001155 isoelectric focusing Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000002731 protein assay Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical class O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000000533 capillary isoelectric focusing Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000005350 fused silica glass Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- -1 xanthenes Chemical class 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101100075829 Caenorhabditis elegans mab-3 gene Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 150000004845 diazirines Chemical class 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002090 nanochannel Substances 0.000 description 1
- 150000004893 oxazines Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229920000208 temperature-responsive polymer Polymers 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003732 xanthenes Chemical class 0.000 description 1
- 238000007693 zone electrophoresis Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
- G01N27/44721—Arrangements for investigating the separated zones, e.g. localising zones by optical means
- G01N27/44726—Arrangements for investigating the separated zones, e.g. localising zones by optical means using specific dyes, markers or binding molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44717—Arrangements for investigating the separated zones, e.g. localising zones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44704—Details; Accessories
- G01N27/44743—Introducing samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
- G01N27/44756—Apparatus specially adapted therefor
- G01N27/44795—Isoelectric focusing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781790P | 2018-12-19 | 2018-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2955171T3 true ES2955171T3 (es) | 2023-11-29 |
Family
ID=69410996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19218272T Active ES2955171T3 (es) | 2018-12-19 | 2019-12-19 | Aplicaciones CE-Western para el desarrollo de anticuerpos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11782023B2 (enExample) |
| EP (2) | EP3671200B1 (enExample) |
| JP (1) | JP2020101545A (enExample) |
| CA (1) | CA3065460A1 (enExample) |
| DK (1) | DK3671200T3 (enExample) |
| ES (1) | ES2955171T3 (enExample) |
| FI (1) | FI3671200T3 (enExample) |
| HU (1) | HUE062818T2 (enExample) |
| PL (1) | PL3671200T3 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3140713A1 (en) * | 2019-05-21 | 2020-11-26 | Regeneron Pharmaceuticals, Inc. | Methods for identifying and quantitating host cell protein |
| EP4493921A1 (en) * | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002582A (en) | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
| US6087188A (en) | 1992-11-13 | 2000-07-11 | Alk A/S | Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand |
| ATE215696T1 (de) | 1993-12-23 | 2002-04-15 | Tropix Inc | Chemilumineszenz-assay mittels energietransfer |
| DE69605712T2 (de) | 1995-03-31 | 2000-04-27 | Laboratory Of Molecular Biophotonics, Hamakita | Anwendung von isoelektrischen Punkt Markern bei der isoelektrischen Fokussierung mit Fluoreszenzdetektierung |
| US6165800A (en) | 1997-05-30 | 2000-12-26 | Bayer Corporation | Chemiluminescent energy transfer conjugates and their uses as labels in binding assays |
| US6126870A (en) | 1997-09-12 | 2000-10-03 | Lumigen, Inc. | Chemiluminescent labeling compounds |
| US6254634B1 (en) | 1998-06-10 | 2001-07-03 | Surmodics, Inc. | Coating compositions |
| CA2306752C (en) | 1998-08-14 | 2008-11-18 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Chemiluminescent reagent and chemiluminescent analysis using the same |
| US6613513B1 (en) | 1999-02-23 | 2003-09-02 | Caliper Technologies Corp. | Sequencing by incorporation |
| JP2001249079A (ja) | 1999-12-28 | 2001-09-14 | Fujirebio Inc | 発光量調節剤を用いた化学発光測定方法及び酵素免疫測定方法 |
| WO2006014680A1 (en) * | 2004-07-19 | 2006-02-09 | Cell Biosciences, Inc. | Methods and devices for analyte detection |
| WO2007035864A2 (en) | 2005-09-20 | 2007-03-29 | Cell Biosciences, Inc. | Electrophoresis standards, methods and kits |
| US20090023156A1 (en) * | 2007-07-20 | 2009-01-22 | Voss Karl O | Methods and reagents for quantifying analytes |
| RU2522002C2 (ru) * | 2009-06-26 | 2014-07-10 | Ридженерон Фармасьютикалз, Инк. | Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом |
| US9766206B2 (en) * | 2013-09-27 | 2017-09-19 | ProteinSimple | Apparatus, systems, and methods for capillary electrophoresis |
| JP7240812B2 (ja) * | 2015-05-12 | 2023-03-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 多量体タンパク質の純度の決定 |
-
2019
- 2019-12-17 US US16/716,734 patent/US11782023B2/en active Active
- 2019-12-18 CA CA3065460A patent/CA3065460A1/en active Pending
- 2019-12-19 FI FIEP19218272.3T patent/FI3671200T3/fi active
- 2019-12-19 EP EP19218272.3A patent/EP3671200B1/en active Active
- 2019-12-19 JP JP2019228754A patent/JP2020101545A/ja not_active Ceased
- 2019-12-19 DK DK19218272.3T patent/DK3671200T3/da active
- 2019-12-19 PL PL19218272.3T patent/PL3671200T3/pl unknown
- 2019-12-19 EP EP23180401.4A patent/EP4253950A3/en not_active Withdrawn
- 2019-12-19 ES ES19218272T patent/ES2955171T3/es active Active
- 2019-12-19 HU HUE19218272A patent/HUE062818T2/hu unknown
-
2023
- 2023-06-23 US US18/213,390 patent/US20230417701A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI3671200T3 (fi) | 2023-08-28 |
| JP2020101545A (ja) | 2020-07-02 |
| DK3671200T3 (da) | 2023-08-21 |
| US20200200707A1 (en) | 2020-06-25 |
| PL3671200T3 (pl) | 2023-10-09 |
| EP3671200B1 (en) | 2023-06-21 |
| EP4253950A3 (en) | 2024-01-17 |
| US20230417701A1 (en) | 2023-12-28 |
| EP4253950A2 (en) | 2023-10-04 |
| US11782023B2 (en) | 2023-10-10 |
| CA3065460A1 (en) | 2020-06-19 |
| EP3671200A1 (en) | 2020-06-24 |
| HUE062818T2 (hu) | 2023-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Goyon et al. | From proof of concept to the routine use of an automated and robust multi-dimensional liquid chromatography mass spectrometry workflow applied for the charge variant characterization of therapeutic antibodies | |
| ES2881359T3 (es) | Determinación de la pureza de proteínas multiméricas | |
| US10753859B2 (en) | Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates | |
| KR102710422B1 (ko) | 모세관 전기영동에 의한 순도 결정 방법 | |
| US20230417701A1 (en) | Ce-western applications for antibody development | |
| US20090023156A1 (en) | Methods and reagents for quantifying analytes | |
| Abbood | Optimization of the Imaged cIEF Method for Monitoring the Charge Heterogeneity of Antibody‐Maytansine Conjugate | |
| BR112021013716A2 (pt) | Análise microfluídica nativa ce-ms de heterogeneidade de carga de anticorpo | |
| Han et al. | High throughput profiling of charge heterogeneity in antibodies by microchip electrophoresis | |
| KR102799360B1 (ko) | 숙주 세포 단백질 동정 및 정량화 방법 | |
| HK40100640A (en) | Ce-western applications for antibody development | |
| US10393701B2 (en) | Microfluidic methods of assaying molecule switching and devices for practicing the same | |
| HK40032088B (en) | Ce-western applications for antibody development | |
| HK40032088A (en) | Ce-western applications for antibody development | |
| EA048742B1 (ru) | Способы идентификации и количественного определения белка клетки-хозяина | |
| JP6157862B2 (ja) | 標的物質−レセプター複合体と遊離レセプターとを分離する方法 | |
| ES3041610T3 (en) | Systems and methods for affinity capillary electrophoresis | |
| Opallage | Advancing Biomolecular Analysis through Capillary Electrophoresis Techniques | |
| Ning et al. | Characterization of ADCs by Capillary Electrophoresis | |
| KR20240164561A (ko) | 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템 | |
| HK40050332B (zh) | 用於亲和毛细管电泳的系统和方法 |